Inflammation and Neuropathy Platform

Inflammation and Neuropathy Technology platform for preclinical R&D is under continuous development:

  • Complete Freund’s Adjuvant (CFA)-induced chronic arthritis

Model of chronic arthritis (unilateral inflammation with systemic symptoms) for integrative investigation of potential analgesic and anti-inflammatory compounds (in mice and rats).

  • Dextran Sodium Sulfate (DSS)-induced murine colitis

Ulcerative colitis for testing potential anti-inflammatory compounds and mechanisms in mice.

  • Lipopolysaccharide-induced acute airway inflammation

Model for integrative testing of acute interstitial pneumonitis and potential anti-inflammatory drugs in mice.

  • Oxazolone-induced Allergic Contact Dermatitis (ACD)

Model of allergic contact dermatitis for testing potential anti-inflammatory/ anti-allergy compounds and mechanisms in mice.

  • Traumatic Mononeuropathy (Chronic Constriction Injury: CCI, SELT-ZER) model

Model of traumatic neuropathy for integrative investigation of the effects and mechanisms of potential novel analgesics (dose-response relation, blood/brain ratio) in mice rats.



Potential end-points include e.g.: functional parameters, in vivo/ex vivo optical imaging and microCT, histopathological evaluation, cytokine and neuropeptide measurements from tissue homogenates/blood, blood, brain, spinal cord, bronchoalveolar lavage fluid (BALF), dorsal root ganglia (biomarkers, growth factors, neuropeptides), cutaneous microcirculation and neurogenic vasodilatation, cytokine measurements, Disease Activity Index, myeloperoxidase enzyme activity, etc.